“…The wider programme has been described elsewhere (Carpenter et al, 2017; Crouse et al, 2020; Hermens et al, 2015) but briefly, involved administration of a protocol of self‐report questionnaires, interview‐based clinician‐rated scales, a neuropsychological test battery, and neuroimaging. While studies of this sample have examined relationships among WM and neurocognition, clinical stage, and alcohol/substance use (Hatton et al, 2014; Hermens et al, 2018, 2019, 2022; Lagopoulos, Hermens, Hatton, Battisti, et al, 2013; Lagopoulos, Hermens, Hatton, Tobias‐Webb, et al, 2013; Sacks et al, 2021), this is the first to examine WM integrity in a predictive framework and the first to examine sleep quality and chronotype. The participants were excluded if they met any of the following: (a) history of neurological disease, (b) medical illness known to affect cognitive/brain function, (c) received electroconvulsive therapy in the 3 months before assessment, (d) clinically evident intellectual disability, or (e) insufficient understanding of the English language to participate in testing.…”